English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, March 6, 2023
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
エーザイ、「LEQEMBI」についてアルツハイマー病治療薬としてフル承認に向けた生物製剤承認一部変更申請(sBLA)が米国FDAに受理され、優先審査に指定
Thursday, March 2, 2023
バイオジェン・ジャパンとエーザイの日本における多発性硬化症治療剤の共同販促について
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan
Tuesday, February 28, 2023
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」の中国における生物ライセンス申請(BLA)が優先審査に指定
Tuesday, February 21, 2023
Dissolution of Bracco-Eisai Joint Venture
Monday, February 20, 2023
ブラッコ・エーザイの合弁解消について
Monday, January 30, 2023
Lecanemab Receives Priority Review Status in Japan
エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、日本において優先審査品目に指定

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575